Philippines Medical Device Regulator: FDA and CDRRHR

1. Key takeaways

Medical devices in the Philippines are regulated by the Food and Drug Administration (FDA), an agency under the Department of Health (DOH). Implementation sits with the Center for Device Regulation, Radiation Health and Research (CDRRHR). The parent statute is the Food, Drug, Device and Cosmetic Act of 1963 (Republic Act No. 3720), which remains the mother law as amended by the Food and Drug Administration Act of 2009 (Republic Act No. 9711). Authorisation detail is layered on top through DOH Administrative Orders and FDA Circulars rather than through a single consolidated device regulation.

The architecture matters commercially, because each layer answers a different question. The Act defines what is prohibited and what the penalty is. The Administrative Order defines classification, authorisation types and the fee system. The Circular defines phased implementation and special pathways. The Advisory defines the operating position in force on a given date. A submission that cites the wrong layer is returned at the window before any technical review begins, and the loss of queue position is rarely recoverable within the same planning cycle.

• Regulator: FDA Philippines under the DOH; devices and IVDs are handled by CDRRHR.
• Mother law: RA No. 3720 as amended by RA No. 9711, the FDA Act of 2009.
• Prohibited acts: Section 11 of RA 9711, including Section 11(k) on operating without an LTO.
• Penalties: Section 12 of RA 9711, with administrative sanctions under Section 29-A.
• Enforcement reach: public health warnings are copied to law enforcement agencies, local government units and the Bureau of Customs, so border clearance is part of compliance rather than a separate commercial matter.

2. Legal basis

Four instruments carry most of the operational weight. AO No. 2018-0002 of 26 January 2018 sets the authorisation framework under which CMDN and CMDR applications are filed. AO No. 2024-0015 of November 2024 sets establishment licensing and has replaced AO No. 2020-0017. AO No. 2024-0016, effective 12 January 2025, sets fees but is currently suspended, so AO No. 50 s. 2001 applies during the suspension. AO No. 2025-0030, effective 6 May 2026, sets post-market obligations. Processing times rest on RA No. 11032, and the one percent Legal Research Fund surcharge rests on RA No. 3870 as amended by PD 200 and PD 1856.

3. Expert insights

Insight one: there are four legal levels, and citing the wrong one sends the filing back.

The most frequent error we see in projects is a client citing an FDA Circular as if it were the statute, or arguing an operational detail out of a section of the Act that was never drafted for that purpose. The division of labour is consistent. The Act establishes prohibitions and penalties. The AO establishes classification, authorisation types and the fee system. The Circular establishes phased implementation and dedicated pathways. The Advisory establishes the position in force for the current period. Ask the Act whether conduct is punishable, the AO what must be filed, and the Circular and Advisory whether a pathway is open today. Mixing these three questions into one citation is what triggers a deficiency at the completeness check rather than at technical review.

Insight two: CDRRHR is the approval hub, but the enforcement chain reaches customs and local government.

CDRRHR performs technical evaluation and issues the certificate, yet the working enforcement network of the FDA also includes the Regional Field Offices (RFO), the Field Regulatory Operations Office (FROO) and FDA laboratories. Public health warnings on unregistered devices show the pattern clearly. A single Advisory, such as FDA Advisory No. 2026-1257, is copied simultaneously to law enforcement agencies (LEA) and local government units (LGU), and directs the Bureau of Customs to intercept entry. Holding a certificate is therefore only half of compliance. The clearance stage verifies registration status independently, which means an unregistered consignment can be stopped even where the commercial documents are in order.

Insight three: devices and drugs share one mother law but sit in different centres.

RA 9711 is a single statute covering food, drugs, cosmetics, devices and in vitro diagnostics, and the FDA organises its centres by product category. Medical devices and IVDs fall to CDRRHR. A common misreading among manufacturers is to treat the FDA as a drug authority and to underestimate its jurisdiction over devices. In fact, Section 11 of RA 9711 lists manufacture, import, export, sale, offer for sale, distribution, transfer, non-consumer use, promotion, advertising and sponsorship of an unauthorised device as prohibited acts. That list is considerably wider than the ordinary commercial understanding of selling, and it captures activities that marketing teams tend to regard as pre-commercial.

4. Practical recommendations

• Build the regulatory ledger before discussing commercial terms. List every applicable Act, AO, FC and Advisory by publication date, marking the effective date of each instrument and its replacement relationships. Replacement chains in the Philippines are unusually tangled, since parts of FC 2021-002-C have already been amended or repealed by FC 2024-003, and a maintained ledger is the only reliable way to avoid citing a clause that no longer exists.
• Put customs verification into the launch sequence. Before a consignment arrives, confirm that the certificate status can be retrieved on the FDA Verification Portal at verification.fda.gov.ph. This prevents the demurrage cost of a shipment that lands while its certificate is still under review, a situation in which neither the broker nor the distributor can release the goods.
• Write the Section 11 list into distributor agreements. Philippine distribution contracts should state expressly that promotion, advertising and sponsorship are not permitted before authorisation. These activities are prohibited acts in their own right and are the ones most often overlooked, because they are handled by commercial staff who never read the statute.

5. Verification checklist

• □ Confirm the competent authority and the implementing centre against the CDRRHR function statement on the FDA website.
• □ Confirm the mother law and its amendment chain by comparing the text of RA 3720 with RA 9711.
• □ Confirm the full list of prohibited acts against Section 11 of RA 9711.
• □ Confirm which fee order currently applies through FDA Advisory No. 2025-0032 and the latest DOH department issuance.
• □ Confirm establishment licensing rules against AO No. 2024-0015, which has replaced AO 2020-0017.
• □ Confirm the registration number format on labels: DVR-xxx, MDR-xxx, IVDR-xxx or RR-xxx, per the FDA advisory position.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across Southeast Asia, including the Philippines. Our team prepares CMDN/CMDR dossiers to ASEAN CSDT structure, manages submissions and deficiency responses with the FDA Philippines, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com